Immunosuppression affects the rate of recurrent primary biliary cirrhosis after liver transplantation.
Identifying the risk factors associated with recurrence of primary biliary cirrhosis after liver transplantation may affect immunosuppression and increase understanding of the pathogenesis. Four hundred eighty-five patients with PBC were followed for a median of 79 months after transplantation; histological evidence of recurrence was found in 23%. On multivariate analysis, the only risk factor identified with recurrence was the type of calcineurin inhibitor used. The odds ratio for recurrence on tacrolimus was 2.73 (95% confidence interval: 1.84-4.10) compared with cyclosporine. For those receiving cyclosporine, the median time to recurrence was 123 months and for those on tacrolimus 62 months (P <.001). Reasons for this difference between the 2 calcineurin inhibitors are not clear.
Neuberger
James
J
Liver Unit, Queen Elizabeth Hospital, Birmingham, UK. J.M.Neuberger@bham.ac.uk
Gunson
Bridget
B
Hubscher
Stefan
S
Nightingale
Peter
P
D000328:Adult; D000368:Aged; D019703:Calcineurin; D016572:Cyclosporine / Q000009:adverse effects*; D004791:Enzyme Inhibitors / Q000009:adverse effects*; D005260:Female; D006801:Humans; D007166:Immunosuppressive Agents / Q000009:adverse effects*; D008105:Liver Cirrhosis, Biliary / Q000209:etiology* / Q000601:surgery; D016031:Liver Transplantation / Q000009:adverse effects* / Q000276:immunology; D008297:Male; D008875:Middle Aged; D012008:Recurrence; D016559:Tacrolimus / Q000009:adverse effects*
D004791:Enzyme Inhibitors; D007166:Immunosuppressive Agents; D016572:Cyclosporine; D019703:Calcineurin; D016559:Tacrolimus